Meridian Bioscience

Meridian Bioscience Financial Debt Ratio

The Financial Debt Ratio of Meridian Bioscience (VIVO) as of Oct 26, 2026 is 5.40 %. In the previous year, Financial Debt Ratio was 13.34 % — a change of -59.54% (lower).

Financial Debt Ratio

5.40 %

YoY

-59.54%

Last updated:

Financial Debt Ratio of Meridian Bioscience is 2022 5.40 % . Financial Debt Ratio of Meridian Bioscience was 2021 13.34 % . It decreases by -59.54% lower compared to the previous year.

The Meridian Bioscience Financial Debt Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Debt Ratio
Date
Financial Debt Ratio
Jan 1, 2015
0.00 USD
Jan 1, 2016
23.17 USD
Jan 1, 2017
21.86 USD
Jan 1, 2018
19.97 USD
Jan 1, 2019
23.29 USD
Jan 1, 2020
16.98 USD
Jan 1, 2021
13.34 USD
Jan 1, 2022
5.40 USD
The Meridian Bioscience Financial Debt Ratio history
YEARFinancial Debt RatioYoY
5.40 %-59.54%
13.34 %-21.40%
16.98 %-27.11%
23.29 %+16.62%
19.97 %-8.64%
21.86 %-5.68%
23.17 %—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

Financial Debt Ratio of Meridian Bioscience is 5.40 % in 2022.

Financial Debt Ratio of Meridian Bioscience changed from 13.34 % to 5.40 %, representing a -59.54% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Debt Ratio Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

The financial debt ratio measures interest-bearing financial debt as a percentage of total assets. It isolates funded debt from trade and other non-financial obligations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Debt Ratio's Meridian Bioscience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Meridian Bioscience

All Key Metrics — Meridian Bioscience